新诊断上皮性卵巢癌女性腹股沟淋巴结转移的发生率及预后意义
这项回顾性单机构队列研究纳入2009至2017年562例III/IV期上皮性卵巢癌患者,18例(3.2%)诊断时存在腹股沟淋巴结转移。腹股沟淋巴结转移未显著影响无进展生存期和总生存期,但达到无肉眼残留病灶的切除与无进展生存期改善相关。
要点
- 晚期上皮性卵巢癌诊断时腹股沟淋巴结转移发生率为3.2%(18/562)。
- 腹股沟淋巴结转移组与无转移组相比,无进展生存期和总生存期无显著差异。
- 腹股沟淋巴结转移患者中,达到无肉眼残留病灶切除者无进展生存期优于非最佳切除者。
核心结论
- 在该回顾性队列研究中,3.2%的晚期上皮性卵巢癌女性诊断时存在腹股沟淋巴结转移。
- 腹股沟淋巴结转移与分别比较的所有III/IV期和IVB期患者相比,未预示更差的临床结局。
- 切除至无肉眼残留病灶与无进展生存期改善相关。
研究设计与样本
- 经IRB批准的回顾性单机构队列研究,纳入2009至2017年III/IV期上皮性卵巢癌女性。
- 通过临床或影像学识别腹股沟淋巴结肿大(定义为短轴>1 cm)的患者。
- 评估腹股沟淋巴结转移对无进展生存期和总生存期的影响。
主要发现
- 562例晚期上皮性卵巢癌女性中,18例(3.2%)诊断时存在腹股沟淋巴结转移,占所有IVB期患者(n=70)的25.7%。
- 5例(27.7%)存在已知的上皮性卵巢癌遗传易感,包括BRCA1(11.1%,n=2)、BRCA2(11.1%,n=2)和BRIP1(5.6%,n=1)。
- 大多数患者接受最佳初次肿瘤细胞减灭术(83.3%,n=15),包括腹股沟淋巴结转移灶减灭,其中50%(n=9)术后无肉眼残留病灶。
- 腹股沟淋巴结转移的III/IV期患者、无腹股沟淋巴结转移的III/IV期患者和无腹股沟淋巴结转移的IVB期患者,无进展生存期分别为19.9、19.9和17.2个月(p=0.84),总生存期分别为137.2、52.9和67.6个月(p=0.29),均无差异。
- 腹股沟淋巴结转移患者中,最佳切除至无肉眼病灶者对比非最佳切除者,无进展生存期分别为27.4和14.3个月(p=0.019);总生存期分别为137.2和57.3个月(p=0.24),未达统计学显著。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE(S): To assess incidence and oncologic outcomes in women with advanced epithelial ovarian cancer (EOC) with inguinal lymph node metastasis (ILNM) at diagnosis. METHODS: An IRB-approved, retrospective single-institution cohort study was performed in women with stage III/IV EOC from 2009 to 2017. Patients with inguinal lymphadenopathy (defined as >1 cm in short axis) clinically or radiographically were identified. The impact of ILNM on progression-free survival (PFS) and overall survival (OS) were assessed. RESULTS: Of the 562 women with advanced EOC, 18 (3.2%) had ILNM at diagnosis, accounting for 25.7% of all patients with stage IVB disease (n = 70). Five patients (27.7%) had a known genetic predisposition for EOC, including BRCA1 (11.1%, n = 2), BRCA2 (11.1%, n = 2) and BRIP1 (5.6%, n = 1). The majority of patients underwent optimal primary cytoreductive surgery (CRS), including debulking of inguinal nodal metastasis (83.3%, n = 15), with 50% (n = 9) having no gross residual disease after surgery. There was no difference in PFS (19.9 vs. 19.9 vs. 17.2 months, p = 0.84) or OS (137.2 vs. 52.9 vs. 67.6 months, p = 0.29) in women with stage III/IV with ILNM, stage III/IV without ILNM, and stage IVB disease without ILNM, respectively. Progression-free survival was improved in women with ILNM who underwent an optimal resection to no macroscopic disease vs. non-optimal resection (27.4 vs. 14.3 months, p = 0.019). Median overall survival at the time of analysis did not reach statistical significance (137.2 vs. 57.3 months, p = 0.24). CONCLUSION(S): In this retrospective cohort study, 3.2% of women with advanced EOC presented with ILNM at diagnosis. Although ILNM did not portend worse clinical outcomes compared to all Stage III/IV and Stage IVB patients, respectively, resection to no gross residual disease was associated with improved PFS.
引用
- Chalif J, Yao M, Gruner M, et al. Incidence and prognostic significance of inguinal lymph node metastasis in women with newly diagnosed epithelial ovarian cancer. Gynecol Oncol. 2022. PMID: 35272875. doi:10.1016/j.ygyno.2022.01.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。